4570 Immuno-Biological Laboratories Co., Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4570

TSE Growth

Immuno-Biological Laboratories Co., Ltd.

1,450

JPY

(+0.35%)

Mar 13, 3:30 pm JST

9.09

USD

Mar 13, 2:30 am EDT

Result

PTS

outside of trading hours

1,450.5

Mar 13, 11:57 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	647	-122	-243	-258	-27.8	0	May 13, 2022	J-GAAP
Mar, 2023	794	57	-149	-289	-31.1	0	May 12, 2023	J-GAAP
Mar, 2024	816	104	125	186	20.1	0	May 14, 2024	J-GAAP
Mar, 2025	969	209	209	249	26.7	0	May 14, 2025	J-GAAP
Mar, 2026 Guidance	1,025	240	240	265	28.5	6	May 14, 2025	J-GAAP
YoY	+5.8%	+14.8%	+14.8%	+6.4%	+6.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 14, 2020	ー	ー	ー	ー	0	J-GAAP
- - - -	Aug 6, 2020	549	-308	-410	-430	0	J-GAAP
Results	May 14, 2021	602	-240	-310	-318	0	J-GAAP
Mar, 2022	May 14, 2021	Available in future release
	Mar 15, 2022
Results	May 13, 2022
Mar, 2023	May 13, 2022
	Apr 27, 2023
Results	May 12, 2023
Mar, 2024	May 12, 2023
	May 10, 2024
Results	May 14, 2024
Mar, 2025	May 14, 2024
	Feb 18, 2025
Results	May 14, 2025
Mar, 2026	May 14, 2025	1,025	240	240	265	6	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2002	825	－	Available in future release
Mar, 2003	1,001	+21.3
Mar, 2004	1,086	+8.5
Mar, 2005	1,110	+2.2
Mar, 2006	1,502	+35.3
Mar, 2007	1,533	+2.1
Mar, 2008	1,288	-16.0
Mar, 2009	1,036	-19.6
Mar, 2010	1,059	+2.2
Mar, 2011	1,059	0.0
Mar, 2012	915	-13.6
Mar, 2013	800	-12.6
Mar, 2014	670	-16.3
Mar, 2015	729	+8.8
Mar, 2016	717	-1.6
Mar, 2017	741	+3.3
Mar, 2018	758	+2.3
Mar, 2019	781	+3.0
Mar, 2020	576	-26.2
Mar, 2021	602	+4.5
Mar, 2022	647	+7.5
Mar, 2023	794	+22.7
Mar, 2024	816	+2.8
Mar, 2025	969	+18.8
Mar, 2026 Guidance	1,025	+5.8	240	+14.8	240	+14.8	28.5	+6.7

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	816	104	12.8	15.88	12.19	0.53	20.1
Mar, 2025	969	209	21.6	17.92	14.38	0.56	26.7
Mar, 2026 Guidance	1,025	240	23.4	15.04	12.71	0.49	28.5

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,533	209	209	249	26.7
Fiscal Year	Mar, 2007	Mar, 2025	Mar, 2025	Mar, 2025	Mar, 2025

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	501	111	-20	-153	-16.5	0	May 12, 2023	J-GAAP
Oct - Mar, 2023	451	91	95	160	17.3	0	May 14, 2024	J-GAAP
Oct - Mar, 2024	525	141	145	178	19.1	0	May 14, 2025	J-GAAP
Oct - Mar, 2025 Guidance	540	98	91	124	13.3	6	Nov 13, 2025	J-GAAP
YoY	+2.9%	-30.5%	-37.2%	-30.3%	-30.4%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	57	56	26	30	0	561	39.12	J-GAAP
Mar, 2024	104	109	133	-24	0	674	41.66	J-GAAP
Mar, 2025	209	130	183	-53	-31	770	41.73	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2023	548	10	25	20	2.2	20.0	Feb 2, 2024	J-GAAP
Apr - Dec, 2024	680	124	129	133	14.3	61.7	Feb 10, 2025	J-GAAP
Apr - Dec, 2025	742	223	236	248	26.7	98.3	Feb 12, 2026	J-GAAP
YoY	+9.1%	+79.8%	+82.9%	+86.5%	+86.1%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	268	94	100	166	17.9	35.1	May 14, 2024	J-GAAP
Apr - Jun, 2024	229	51	56	51	5.5	22.3	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	215	17	8	20	2.2	7.9	Nov 11, 2024	J-GAAP
Oct - Dec, 2024	236	56	65	62	6.7	23.7	Feb 10, 2025	J-GAAP
Jan - Mar, 2025	289	85	80	116	12.5	29.4	May 14, 2025	J-GAAP
Apr - Jun, 2025	211	54	57	60	6.5	25.6	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	274	88	92	81	8.7	32.1	Nov 13, 2025	J-GAAP
Oct - Dec, 2025	257	81	87	107	11.5	31.5	Feb 12, 2026	J-GAAP
YoY	+8.9%	+44.6%	+33.8%	+72.6%	+72.2%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	188	+0.5	Available in future release
Apr - Jun, 2021	125	+7.8
Jul - Sep, 2021	128	-2.3
Oct - Dec, 2021	195	+16.8
Jan - Mar, 2022	199	+5.9
Apr - Jun, 2022	156	+24.8
Jul - Sep, 2022	137	+7.0
Oct - Dec, 2022	261	+33.8
Jan - Mar, 2023	240	+20.6
Apr - Jun, 2023	177	+13.5
Jul - Sep, 2023	188	+37.2
Oct - Dec, 2023	183	-29.9
Jan - Mar, 2024	268	+11.7
Apr - Jun, 2024	229	+29.4
Jul - Sep, 2024	215	+14.4
Oct - Dec, 2024	236	+29.0
Jan - Mar, 2025	289	+7.8
Apr - Jun, 2025	211	-7.9
Jul - Sep, 2025	274	+27.4
Oct - Dec, 2025	257	+8.9	81	+44.6	87	+33.8	11.5	+71.6

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	606	238	234	227	24.2
Fiscal Year	Dec, 2006	Dec, 2006	Dec, 2006	Dec, 2006	Mar, 2008

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	115.81	75.2	1,434	1,078	-4,009	0.22	May 12, 2023	J-GAAP
Mar, 2024	135.85	78.2	1,618	1,265	176	0.19	May 14, 2024	J-GAAP
Mar, 2025	162.60	82.1	1,845	1,514	425	0.13	May 14, 2025	J-GAAP
Apr - Dec, 2025	ー	84.5	2,085	1,762	674	0.10	Feb 12, 2026	J-GAAP

Immuno-Biological Laboratories Co., Ltd.(4570) Financial Results